Navigation Links
Impliant Granted Two New U.S. Patents and Successfully Defends European Patent Opposition Case
Date:6/9/2009

PRINCETON, N.J., June 9 /PRNewswire/ -- Impliant, Inc., a developer of novel spine arthroplasty alternatives to fusion surgery, today announced that the European Patent Office has confirmed the validity of one of its key patents following an Opposition by Archus Orthopedics, Inc. (Redmond, WA) that concluded with oral proceedings on May 12, 2009 in Munich, Germany. This patent (EP1578314 B1), originally issued to Impliant on May 30, 2007, involves among others the company's flagship product, the TOPS System, a Total Posterior Arthroplasty device designed to treat lumbar spinal stenosis with or without facet arthrosis and spondylolisthesis. Archus challenged the patent on the grounds of being too broad, but the European Patent Office rejected the opposition and upheld every claim of the patent.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080527/NETU060LOGO )

Impliant also announced that it has been granted two additional patents in the United States. The first (US 7537613), granted on May 26, 2009, is another patent that directs to the company's TOPS System. The second (US 20050197705), already a patent in Europe (EP1646338), entails a unique translateral spinal disc replacement.

"We are very pleased by the outcome of these procedings," said Todd Potokar, President and CEO of Impliant. "The successful defense of one of our main patents in Europe coupled with the addition of two new patents in the U.S. further strengthens our robust IP portfolio."

Impliant is applying cutting-edge materials and crossbar biomechanical techniques to develop a new class of spine arthroplasty devices that target over 40% of the patients worldwide who undergo fusion surgery and could benefit from a Total Posterior Arthroplasty solution.

About the TOPS(TM) System

Impliant's TOPS(TM) System, a mobile posterior device, is designed to stabilize but not fuse the L3-4 or L4-5 vertebral level to alleviate pain stemming from spinal stenosis with or without degenerative facet arthrosis, and spondylolisthesis. Following a laminectomy and medial facetectomy, the device is affixed to the spine via four pedicle screws using a standard posterior surgical approach. Impliant believes that the TOPS(TM) System could benefit over 500,000 patients worldwide undergoing spinal fusion surgery each year. The TOPS(TM) System is not approved for sale in the United States.

About Impliant, Inc.

Impliant, Inc. is a privately held company engaged in the development of novel spine arthroplasty solutions for some of the most prevalent pathologies of the spine. The company is currently developing the TOPS(TM) System, which has the longest clinical history in the Total Posterior Arthroplasty market segment, dating to January 2005. Impliant is also developing several next-generation and multi-level technologies to further increase its addressable market. Impliant is headquartered in Princeton, NJ with research facilities located in Ramat Poleg, Israel. Shareholders include Elron Electronic Industries Ltd. (Nasdaq & TASE: ELRN). For more information about Impliant, please visit www.impliant.com.


'/>"/>
SOURCE Impliant, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Impliant Restarts European Clinical Activities for Patented TOPS(TM) Spine System
2. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
3. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
4. USC granted $8.4 million for autism research
5. Aida Granted Additional Anti-Cancer Patent
6. CME LLC Granted Five-Year Full Approval by the American Psychological Association
7. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
8. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
9. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
10. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
11. Phylonix granted broad European patent for transplanting human cells into zebrafish
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... Boca Raton, Florida (PRWEB) , ... April 24, 2017 , ... ... natural chai teas, announced its products are now available for purchase on RevNutrition.com, a ... ancient form of tea first produced and popularized in ancient India and Siam. It ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... healthcare compliance and credentialing solutions, today announced that Kyle Allain has joined the ... Cactus Provider Management sales and operations, including provider, payor and managed care solutions. ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... to be diagnosed globally; approximately 25,000 of them will be malignant.(1) As research ... of this type of healthcare model in the diagnosis and treatment of brain ...
(Date:4/24/2017)... IL (PRWEB) , ... April 24, 2017 , ... Rod ... the Senior Housing News website. , Rod has been at the forefront of Gardant ... company’s culture. As CEO, Rod has overseen the opening of more than 40 new ...
(Date:4/24/2017)... ... April 24, 2017 , ... As a former supermodel known for ... The good news for single women is that she put all the words in ... April 25th. Joan's insight, personal experiences and sparkling sense of humor have inspired her ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Cogentix Medical, Inc. (NASDAQ: ... providing the Urology, Uro/Gyn and Gynecology markets with ... Keswani has joined the Company as Senior Vice ... created position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has ...
(Date:4/20/2017)... 20, 2017  RXi Pharmaceuticals Corporation (NASDAQ: RXII), ... address significant unmet medical needs, today announced that ... consumer product development program, based on its proprietary ... Investigative Dermatology (SID) 76 th Annual Meeting.  ... the sciences relevant to skin health and disease ...
(Date:4/20/2017)... -- AbbVie (NYSE: ABBV), a global biopharmaceutical company, today ... C virus (HCV) infected patients with genotype 1, ... (Child-Pugh A) achieved sustained virologic response at 12 ... pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These high SVR ... of G/P treatment without ribavirin. Patients with specific ...
Breaking Medicine Technology: